LEXINGTON, Mass., Nov. 13,
2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an
immuno-oncology company with a pipeline of immune modulating
antibodies, cancer vaccines, and adoptive cell
therapies1, today announced the election of Dr.
Allison Jeynes-Ellis to Agenus'
Board of Directors and the appointment of Dr. Jennifer S. Buell to Chief Operating
Officer.
"As we advance towards becoming a commercial organization, I am
delighted to welcome Dr. Jeynes-Ellis to our Board," said
Garo Armen, PhD, Chairman and CEO of
Agenus. "Allison brings significant global drug development and
commercialization experience which includes executing on global
registrational studies resulting in regulatory approvals in US and
EU and advising on commercialization and reimbursement
strategies. We will benefit from Allison's considerable
development, regulatory, and commercial expertise."
"I am also thrilled with the appointment of Dr. Jennifer Buell to the position of Chief
Operating Officer. Jen has been an integral part of transforming
Agenus into a company with a broad pipeline of first &
best-in-class treatments. Jen's scientific training, more than 20
years of biopharmaceutical experience, and a demonstrated track
record of delivering on our operational commitments underscores her
appointment to lead our operations as we prepare to become a
commercial company."
Agenus' new board member, Allison
Jeynes-Ellis, MD, FFPM (UK), is a trained clinician with
more than 25 years of senior leadership experience in the
pharmaceutical industry. Currently, she serves as Chief Executive
Officer at Avillion LLP, a London-based drug development company focused
on co-development and financing of late-stage pharmaceuticals where
she is responsible for identifying high-potential opportunities to
fund programs to approval. Previously, she led development at
Wyeth, BMS, Novartis, and GSK and has secured numerous U.S. and EU
drug approvals.
Since joining Agenus in 2013, Dr. Buell has served as the Head
of Global R&D operations, Head of Research, and most recently
as Chief Communications and External Affairs Officer. During
her tenure, Jen helped advance the expansion of Agenus from a
neoantigen vaccine company to a global, fully-integrated platform
company with a unique pipeline of immune modulating antibodies,
cancer vaccines, adjuvants, and adoptive cell therapies.
Today, Agenus has major collaborations with Merck and Incyte, a
demonstrated track record of delivering on operational commitments,
and has outpaced pharma in delivering new discoveries to the
clinic. In her new role, Dr. Buell will assume responsibility
for Research, Clinical Development, Manufacturing, Commercial
Operations, and relevant supportive functions.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, proprietary
cancer vaccine platforms, and adoptive cell therapies (through its
AgenTus Therapeutics subsidiary). The Company is equipped with a
suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' clinical
development plans and timelines, the expectation to become a
commercial organization, and the expected contributions of new
board member, Dr. Jeynes-Ellis. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-elects-new-board-member-dr-allison-jeynes-ellis-and-appoints-chief-operating-officer-dr-jennifer-buell-300749582.html
SOURCE Agenus